ClinicalTrials.gg
CompletedNCT05186909Updated Feb 28, 2024

A Study of CM310 in Subjects With Moderate to Severe Asthma

A Phase 2 interventional study of CM310 and Placebo in Asthma, sponsored by Keymed Biosciences Co.Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-02-28.

Sponsored by Keymed Biosciences Co.Ltd · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 251 studies in Asthma with a site in China — 87 open to participants now, 96 under way, 15 of them phase 3. Asthma · China.

Enrollment
141st of 182
52 · median 203
Started
2022
with 20 others
Phase 2
39 of 251
19 open now
Registered
114th of 251
by date

Among the 251 studies in Asthma with a site in China, this one is the 141st largest by enrollment of the 182 interventional ones that give a count, is one of 21 that started in 2022, is one of 39 in phase 2, and was the 114th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

87 of the 251 studies in Asthma with a site in China are open now. Recruiting first, the newest first:

82 more — sign in →

All 87 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 251 studies in Asthma with a site in China, or all of them as a file.
02

Study summary

This study is a multi-center, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM310 in subjects with moderate to severe asthma.

The study consists of three periods, including an up to 4-week screening period, a 24-week randomized treatment period, and a 8-week safety follow-up period.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects are able to understand the nature of the study and voluntarily sign the ICF.
  • Diagnosed with asthma according to the 2021 version of the GINA guidelines for at least 1 year.
  • Pre-bronchodilator measurement ≤ 80% of predicted normal value.
  • Subjects must have experienced a severe asthma exacerbation within 12 months prior to screening, and have not experienced a severe asthma exacerbation within 1 month prior to screening.

Exclusion criteria

Exclusion Criteria:

  • Women of have a positive pregnancy test result during the screening period; women who are pregnant or lactating.
  • Received biologics with the same therapeutic purpose within 6 months prior to screening, such as similar IL-4Rα antagonist, IL-5/5R, anti-IgE monoclonal antibody (mAb).
  • Diagnosed with (COPD) or other lung disorders that may compromise lung function (including but not limited to idiopathic pulmonary fibrosis, allergic granulomatous angiitis, bronchopulmonary aspergillosis allergic, pulmonary tuberculosis, etc.).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    CM310 300mg Q2W

    CM310 is injected subcutaneously (SC) with a loading dose of 600 mg at the first dose, and then 300 mg each time, once every 2 weeks (Q2W) for a total of 12 doses.

    Drug: CM310

  • Experimental
    CM310 150mg Q2W

    CM310 is injected subcutaneously (SC) with a loading dose of 300 mg at the first dose, and then 150 mg each time, once every 2 weeks (Q2W) for a total of 12 doses.

    Drug: CM310

  • Placebo comparator
    Placebo

    Subcutaneous injection (SC), once every 2 weeks (Q2W) for a total of 12 doses.

    Other: Placebo

Interventions

  • DrugCM310

    CM310 Recombinant Humanized Monoclonal Antibody Injection

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Change from baseline in pre-bronchodilator FEV1 (forced expiratory volume in 1 second) at 12 weeks.

    Absolute change from baseline in pre-bronchodilator FEV1 in each dose group at 12 weeks of CM310 treatment compared with placebo.

    Time frame: 12 weeks

Secondary outcomes

  1. Change from baseline in pre-bronchodilator FEV1 at each evaluation time point.

    Absolute change from baseline in pre-bronchodilator FEV1 at each evaluation time point.

    Time frame: 24 weeks

  2. Percent change from baseline in pre-bronchodilator FEV1 at each evaluation time point.

    Percent change from baseline in pre-bronchodilator FEV1 at each evaluation time point.

    Time frame: 24 weeks

  3. Annualized rate of subjects experiencing severe asthma exacerbations.

    Annualized rate of subjects experiencing severe asthma exacerbations during the 24-week randomized treatment period.

    Time frame: 24 weeks

  4. Time to the first onset of the severe asthma exacerbation event.

    Time from baseline to the first onset of the severe asthma exacerbation event.

    Time frame: 24 weeks

  5. Annualized rate of subjects experiencing the event of loss of asthma control (LOAC).

    Annualized rate of subjects experiencing the event of loss of asthma control (LOAC) during the 24-week randomized treatment period.

    Time frame: 24 weeks

  6. Time to the onset of the first event of LOAC.

    Time from baseline to the onset of the first event of LOAC.

    Time frame: 24 weeks

  7. FEV1 percentage of predicted value (FEV1% Pred)

    FEV1 percentage of predicted value (FEV1% Pred)

    Time frame: 32 weeks

  8. Peak diurnal and nocturnal expiratory flow (PEF)

    Peak diurnal and nocturnal expiratory flow (PEF)

    Time frame: 32 weeks

  9. Forced vital capacity (FVC)

    Forced vital capacity (FVC)

    Time frame: 32 weeks

  10. Maximal mid-expiratory flow (MMEF)

    Maximal mid-expiratory flow (MMEF)

    Time frame: 32 weeks

  11. Change from baseline of FEV1 after the use of bronchodilator.

    Change from baseline of FEV1 after the use of bronchodilator.

    Time frame: 32 weeks

  12. Change from baseline in the Asthma Control Questionnaire-5 (ACQ-5) score at each evaluation time point.

    The ACQ-5 is a questionnaire used to evaluate the degree of asthma control. Each question is scored from 0 to 6 (on a 7-point scale) according to its severity. The higher the score, the less satisfactory symptom control is.

    Time frame: 32 weeks

  13. Change from baseline in asthma symptom score at each evaluation time point.

    Patients will record total symptom scores in morning(a 0-4 scale, with 0=no symptoms, 4=inability to fall asleep at night due to symptoms) and afternoon (a 0-5 scale, with 0=no symptoms, 5=severe symptoms, unable to work or perform daily activities).

    Time frame: 32 weeks

  14. Incidence of Adverse events (AEs)

    Incidence of AEs, including any abnormal physical examinations, abnormal vital signs, abnormal ECG, and abnormal lab testing.

    Time frame: 32 weeks

  15. Trough concentration at steady-state of CM310

    To evaluate the trough concentration at steady-state of CM310 for each dose group. Population pharmacokinetic analysis is performed using a nonlinear mixed-effects model.

    Time frame: 32 weeks

  16. Human thymus and activation-regulated chemokine (TARC)

    Change from baseline in TARC at each evaluation time point for each dose group.

    Time frame: 32 weeks

  17. Fractional exhaled nitric oxide (FeNO).

    Change from baseline in FeNO at each evaluation time point for each dose group.

    Time frame: 32 weeks

  18. Total IgE (immunoglobulin E)

    Change from baseline in total IgE at each evaluation time point for each dose group.

    Time frame: 32 weeks

  19. Anti-drug antibodies (ADAs) and neutralizing antibodies (Nabs).

    Incidence of anti-drug antibodies (ADAs) and neutralizing antibodies (Nabs) (if applicable).

    Time frame: 32 weeks

07

Study locations

1 site
  • China-Japan Friendship Hospital
    Beijing, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Sep 2023, 20 months.

Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 20 months is above that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2021
First posted
Jan 11, 2022
StartActual
Jan 12, 2022
Primary completionActual
Sep 13, 2023
CompletionActual
Sep 13, 2023
Last update
Feb 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05186909
Responsible party
Sponsor
First posted
Jan 11, 2022
Start date
Jan 12, 2022
Primary completion
Sep 13, 2023
Completion
Sep 13, 2023
Last update
Feb 28, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Stapokibart

Start the discussion